YOLFTbeta
Ascletis Pharma Inc

Ascletis Pharma Inc

2VJ · F · Healthcare / Biotechnology

0.535EUR-0.02 (-2.73%)

Price History

Full chart

Market Stats

Previous Close0.55
Open0.53
Day Range0.53 – 0.535
52-Week Range0.88 – 2.06
Volume0
Market Cap976.35M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.08
Dividend Yield0.00%
Beta0.39
50-Day Avg1.04
200-Day Avg1.38

About

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Further, it offers ASC30, for obesity; ASC47 for muscle-preserving weight loss treatment; and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Ascletis Pharma Inc. was founded in 2013 and is based in Wan Chai, Hong Kong.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jinzi Wu Ph.D.
  • Employees217
  • HeadquartersDah Sing Financial Centre, Wan Chai, Hong Kong, Germany
  • Websitehttps://www.ascletis.com

Leadership

  • Dr. Jinzi Wu Ph.D.Founder, Chairman & CEO · b. 1963
  • Ms. Hejingdao WuSenior VP of Operations & Executive Director · b. 1974
  • Dr. Kristjan Sigurdur GudmundssonSenior Consultant & Head of Discovery · b. 1968
  • Dr. George Zhengzhi HillSenior Consultant & Chief Medical Advisor · b. 1951
  • Mr. John P. Gargiulo M.B.A.Chief Business Officer · b. 1960

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue32.98M53.20M166.32M173.44M35.00M76.88M54.09M56.60M1.28M2.03M
Growth (%)-+61.34%+212.63%+4.28%-79.82%+119.64%-29.64%+4.63%-97.73%+58.07%
Cost of Revenue0012.38M49.16M58.50M37.70M78.78M30.61M548.00K1.50M
Gross Profit32.98M53.20M153.95M124.28M-23.50M39.17M-24.69M25.99M735.00K527.00K
Gross Margin100.00%100.00%92.56%71.66%-67.13%50.96%-45.65%45.92%57.29%25.99%
Operating Expense75.73M120.39M214.86M225.56M129.44M223.26M314.94M326.20M382.99M447.02M
Operating Income-42.75M-67.19M-60.91M-101.27M-152.94M-184.08M-339.63M-300.21M-382.25M-446.50M
Operating Margin-129.64%-126.29%-36.62%-58.39%-436.95%-239.45%-627.90%-530.44%-29793.84%-22016.57%
EBITDA--61.64M-48.93M-73.64M-181.94M-169.35M-284.50M-126.09M-280.24M-341.59M
EBITDA Margin--115.85%-29.42%-42.46%-519.82%-220.29%-525.97%-222.79%-21842.40%-16843.84%
Net Income-26.81M-53.94M-7.26M-95.97M-209.24M-199.02M-314.84M-144.72M-300.94M-359.88M
Net Income Margin-81.29%-101.38%-4.36%-55.33%-597.81%-258.88%-582.07%-255.70%-23455.65%-17745.56%
R&D62.69M114.33M143.45M125.96M109.10M213.32M267.10M216.78M302.39M409.05M
R&D as % of Total Revenue190.10%214.89%86.25%72.62%311.70%277.49%493.81%383.03%23569.29%20170.27%
Interest Expense000182.00K135.00K125.00K157.00K144.00K244.00K164.00K
Interest Expense % of Total Revenue0.00%0.00%0.00%0.10%0.39%0.16%0.29%0.25%19.02%8.09%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets536.26M991.25M3.53B3.43B3.07B2.83B2.66B2.49B2.12B2.07B
Total Liabilities127.18M121.42M100.19M102.17M85.42M100.89M117.16M148.94M158.41M132.26M
Total Equity272.36M596.96M3.43B3.32B2.98B2.73B2.54B2.34B1.97B1.93B
Cash418.97M607.37M3.17B2.99B2.71B2.50B2.47B330.12M865.73M1.44B

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.50M-198.06M-96.59M-74.34M-84.91M-146.93M-142.45M-223.79M-341.58M-416.78M
Investing Cash Flow-37.63M-644.54M-817.47M602.27M132.30M-274.49M-1.30B---
Financing Cash Flow-549.36M2.56B-48.22M-21.67M-31.10M-1.42M---
Capital Expenditure44.61M15.30M15.82M18.89M4.92M4.97M7.07M19.16M2.15M1.97M
Free Cash Flow--234.00M-156.67M-102.57M-123.87M-154.13M-156.85M-242.95M-343.73M-418.75M
Dividends Paid64.48M57.81M57.81M-------
FCF to OCF-118.15%162.20%137.98%145.88%104.90%110.11%108.56%100.63%100.47%
Dividend Paid to FCF--24.71%-36.90%-------

Key Statistics & Ratios

Market Cap976.35M
Enterprise Value783.53M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1030.99
Price / Book3.58
EPS-0.08
Book Value0.2837
Revenue (TTM)947.00K
Gross Profit (TTM)406.00K
EBITDA-687.02M
Profit Margin0.00%
Operating Margin-73801.48%
Return on Equity-28.59%
Return on Assets-19.64%
Shares Outstanding1.05B
Shares Float211.20M
Beta0.39
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%